Augmented antitumor effects of combination therapy with VEGF antibody and cisplatin on murine B16F10 melanoma cells

International Immunopharmacology

Volumn 7, Issue 13, 2007, Pages 1598-1608

  Ghosh, Sonali ^a   Maity, Putul ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

Author keywords

Angiogenesis; Cisplatin; Melanoma; VEGF

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARBON DIOXIDE; CISPLATIN; GELATINASE B; IMMUNOGLOBULIN G; NITRIC OXIDE; NONESSENTIAL AMINO ACID; PROTEIN BCL 2; VASCULOTROPIN ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER TRANSPLANTATION; CELL CULTURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; IN VITRO STUDY; IN VIVO STUDY; LUNG TUMOR; MALE; MELANOMA CELL; MONOTHERAPY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR VOLUME;

ANIMALS; ANTIBODIES; CELL LINE, TUMOR; CISPLATIN; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 9; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; NITRIC OXIDE; PROTO-ONCOGENE PROTEINS C-BCL-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 35848962527     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2007.08.017     Document Type: Article

References (38)

1. Dvorak H.F., Nagy J.A., Feng D., Brown L.F., and Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 237 (1999) 97-132
2. Yancopoulos G.D., Davis S., Gale N.W., et al. Vascular specific growth factors and blood vessel formation. Nature 407 (2000) 242-248
3. Leung D.W., Cachianes G., and Kuang W.J. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 (1989) 1306-1309
4. Unemori E.N., Ferrara N., Bauer E.A., and Amento E.P. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 153 (1992) 557-562
5. Pepper M.S., Ferrara N., Orci I., and Montesano R. Vascular Endothelial Growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 181 (1991) 902-906
6. Warren R.S., Yuan H., Matli M.R., Gillett N.A., and Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95 (1995) 1789-1797
7. Borgström P., Hillan K.J., Sriramarao P., and Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibodies. Novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 56 (1996) 4032-4039
8. Melnyk O., Schuman M.A., and Kim K.J. Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res 56 (1996) 921-924
9. Asano M., Yukita A., Matsumoto T., Kondo S., and Suzuki H. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to vascular endothelial growth factor/vascular permeability factor. Cancer Res 55 (1995) 5296-5301
10. Yuan F., Chen Y., Dellian M., Safabakhsh N., Ferrara N., and Jain R.K. Time-dependent vascular regression and permeability changes in established xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 93 (1996) 14765-14770
11. Borgstrom P., Gold D.P., Hillan K.J., and Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 19 5B (1999) 4203-4214
12. Folkman J. What is the role of angiogenesis in metastasis from cutaneous melanoma?. Eur J Cancer Clin Oncol 23 (1987) 361-363
13. Claffey K.P., Brown L.F., del Aguila L.F., et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 56 (1996) 172-181
14. Oku T., Tjuvajev J.G., Miyagawa T., et al. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res 58 (1998) 4185-4192
15. Graven U., Fiedler W., Karpinski S., Ergun S., Kilic N., Rodeck U., et al. Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR. J Cancer Res Clin Oncol 125 11 (Nov 1999) 621-629
16. Dabrowska-Iwanicka A., Olszewska D., Jalili A., Makowski M., Grzela T., Marczak M., et al. Augmented antitumor effects of combination therapy with TNP-470 and chemoimmunotherapy in mice. J Cancer Res Clin Oncol 128 8 (Aug 2002) 433-442
17. Ghosh S., and Maity P. Vascular endothelial growth factor immunoneutralization in combination with cisplatin reduces EAC tumor growth. Int Immunopharmacol 6 10 (Oct 2006) 1550-1559
18. Ghosh S., and Maity P. Isolation and purification of vascular endothelial growth factor (VEGF) from ascitic fluid of ovarian cancer patients. Pathol Oncol Res 10 2 (2004) 104-108
19. Kawashima A., Nakanishi I., Tsuchiya H., Roessner A., Obata K., and Okada Y. Expression of matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) induced by tumour necrosis factor alpha correlates with metastatic ability in a human osteosarcoma cell line. Virchows Arch 424 5 (1994) 547-552
20. Danielsen T., and Rosfstad E.K. VEGF, bFGF and EGF in the angiogenesis of human melanoma xenografts. Int J Cancer 76 (1998) 836-841
21. Bosari S. Microvessel quantification and prognosis in invasive breast carcinoma. Hum Pathol 23 (1992) 755-761
22. Jessica C.A., van de Ven M.W.C.M., Forget P.Ph., Brouckaert P., and Burrman W.A. The role of endogenous IFN-∝, TNF-∝ and IL-10 in LPS induced nitric oxide release in a mouse model. Cytokine 10 (1998) 115-123
23. Phizackerley P.J.R., and Ai-Dabbagh A.S. The estimation of nitrate and nitrite in saliva and urine. Anal Biochem 131 (1983) 242-245
24. Green L.C., Waganer D.A., Glogowski J., skipper P.L., Wishnok J.S., and Tannenbaum S.R. Analysis of nitrate nitrite and [15 N] nitrate in biological fluids. Anal Biochem 126 (1982) 131-138
25. Prewett M., Huber J., Li Y., Santiago A., O'Connor W., King K., et al. Antivascular endothelial growth factor receptor (Fetal Liver Kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59 (October 15 1999) 5209-5218
26. Teicher B.A., Sotomayor E.A., and Huang Z.D. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52 (1992) 6702-6704
27. Teicher B.A., Emi Y., Kakeji Y., and Northy D. TNP-470/minocycline/cytotoxic therapy: a systems approach to cancer therapy. Eur J Cancer 32A (1996) 2461-2466
28. Dings R.P., Yokoyama Y., Ramakrishnan S., Griffioen A.W., and Mayo K.H. The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res 63 (2003) 382-385
29. Yang J.C., Haworth L., Sherry R.M., Hwu P., Scwartzentuber D.J., et al. A randomized trail of bevacizumab, an anti-vascular endothelial growth factor anti-body, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
30. Lamoreaux W.J., Fitzgerald M.E., Reiner A., et al. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 55 (1998) 29-42
31. Ekmekcioglu S., Tang C.H., and Grimm E.A. NO news is not necessarily good news in cancer. Curr Cancer Drug Targets 5 2 (2005 Mar) 103-115
32. Griffioen A.W., and Molema G. Angiogenesis: potential for pharmacological intervention in the treatment of cancer, cardiovascular disease and chronic inflammation. Pharm Res 52 (2000) 237-268
33. Zhou J., Zhu Q., and Yao H. [Chemotherapy of non-small-cell lung cancer (NSCLC) and changes in serum sAPO-1/Fas and nitric oxide (NO) levels]. Zhonghua Zhong Liu Za Zhi 22 3 (May 2000) 225-227
34. Beierle E.A., Strande L.F., and Chen M.K. VEGF upregulates Bcl-2 expression and is associated with decreased apoptosis in neuroblastoma cells. J Pediatr Surg 37 3 (Mar 2002) 467-471
35. Mauceri H.J., Hanna N.N., Beckett M.A., Gorski D.H., Staba M.J., Stellato K.A., et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature (Lond.) 394 (1998) 287-291
36. Teicher B.A., Williams J.I., Takeuchi H., Ara G., Herbst R.S., and Buxton D. Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma. Anticancer Res 18 (1998) 2567-2573
37. Wei Y.Q., Wang Q.R., Zhao X., Yang L., Tian L., Lu Y., et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 6 10 (2000) 1160-1166
38. Plum S.M., Holaday J.W., Ruiz A., Madsen J.W., Fogler W.E., and Fortier A.H. Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development. Vaccine 19 (2000) 1294-1303